Close Menu


Nasdaq informed DeCode that it will suspend trading in the company’s common stock as of November 30, 2009.

The court approved Decode to continue operations under Chapter 11 bankruptcy protection, as well as its debtor-in-possession financing agreement with Saga.

Under the partnership, OptumHealth Allies' 15 million members will now have access to Pathway Genomics' health and ancestry gene scans at a 20 percent discount, which brings Pathway's $348 full health and ancestry gene scan package down to $278. Meanwhile, 23andMe's is raising the price of its health and ancestry gene scan package by an additional $100, to $499.

In addition to the filing for bankruptcy protection, Decode also has entered into an agreement to sell certain assets to Saga Investments.

The Mountain View, Calif.-based direct-to-consumer genomics firm has had a round of layoffs that it said were necessary to remain in business in a difficult economic climate. Competing DTC genomics firms have had cutbacks or are proceeding cautiously.

Decode has 30 days to make the interest payment or it will be in default.

Decode increased the principal amount of the promissory note to $2.9 million.

Decode expects that the closure and layoffs will cost it around $1.5 million in cash expenditures. It did not say how much it expects to save from the moves.

Steven Casper, director of the master of bioscience degree program at the Keck Graduate Institute of Applied Life Sciences, discusses a recent report assessing the Los Angeles region's life sciences strengths and shortcomings.

Shares of Decode Genetics stock were up nearly 11 percent in trading today following Decode researchers' identification of new prostate cancer risk variants.


Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.